| Name | Title | Contact Details |
|---|
gloStream Inc. is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Haworth Cleaners is a Haworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 2007 the Delaware Health Information Network (DHIN) became the first live, statewide health information network in the nation. DHIN currently serves: - 100% of Delaware’s acute care hospitals - 100% of Delaware’s long term care and skilled nursing facilities - Approaching 100% of medical providers who have enrolled and are participating in DHIN More than 14,000,000 clinical results and reports are posted on DHIN each year – and the total patient records in the system now exceed 2,100,000, featuring patient records from all 50 states. In the six years that DHIN has been active, the system has proven its reliability and worth to hospitals, medical professionals and patients throughout Delaware. DHIN securely delivers fast and accurate patient information from hospitals, laboratories, and radiology facilities directly to doctors’ offices. DHIN makes it possible to deliver higher quality medical care more quickly, and at a lower cost, using a federated data model for medical records, aggregating those records and eliminating the manual transmittal of medical data. Frequent audits confirm that the system is secure and that data is used properly. The Delaware Health Information Network (DHIN) was enacted by the Delaware General Assembly in 1997 as a public-private partnership for the benefit of all citizens of Delaware to advance the creation of a statewide health information network and to address Delaware`s needs for timely, reliable and relevant health care information.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Driven by a passion for partnership as well as innovation, HOYA has been a partner to Eye Care Professionals for over 75 years, enabling them to give people the greatest gift, the gift of vision. We provide Eye Care Professionals with the lenses, consultation solutions and other services that help them to develop their practice while changing the way people see the world. We see them as visionaries, and everything we do is for them. Founded in Japan in 1941, today, HOYA has a presence in over 80 countries across the globe.